VEC.L Share News (VEC)

WINNERS & LOSERS SUMMARY: Investors Inhale Vectura Group Shares

LONDON MARKET OPEN: Stocks Mixed, IAG Drops Despite Guidance Upgraded

Vectura and Novartis win FDA approval for COPD combo

(ShareCast News) - Vectura and giant Swiss partner Novartis have received US drug regulator approval for their combination treatment for patients with chronic obstructive pulmonary disease (COPD), triggering a sizeable milestone payment for the UK company. The FTSE 250 drug developer and project par

Vectura Gets Two Milestone Payments From Novartis

BROKER RATINGS SUMMARY: Citigroup Upgrades Travis Perkins To Buy

Vectura gets cash payout as lung treatment partner reaches milestone

(ShareCast News) - Medical research firm Vectura said it is to receive a €5m (£3.6m) payment after its secret partner on a lung disease treatment achieved "an important development milestone in Europe". Vectura, which specialises in developing products for treating of airways-related diseases, said

Vectura Group Gets Milestone Payment From VR876 Programme

Vectura triggers new $3m milestone payment for VR315 therapy

(ShareCast News) - Medical research company Vectura Group said it has triggered another $3m (£1.98m) milestone payment for its VR315 treatment. Vectura, which specialises in the development of products for the treatment of airways-related diseases, said it had already earned $9m (£6m) from the deal

Vectura Gets Further USD3 Million Milestone From VR315 Development

AGM, EGM Calendar - Week Ahead

Vectura confident after successful regulatory meeting for asthma drug

(ShareCast News) - Drug company Vectura was upbeat on the development of its VR647 asthma drug following a meeting with the US Food and Drug Administration. Shares in the stock rose 0.28% to 176.70p on the news the FDA approved Vectura's pathway to producing the medication, which is specialised for

Vectura Discusses Plans For Asthma Treatment With US Authorities

WINNERS & LOSERS: Grocers Rise On Broker Notes, Delhaize-Ahold Merger

UPDATE 1-AstraZeneca loses second top executive as Vectura gets new CEO

(Adds context on AstraZeneca, comment from company spokeswoman) By Ben Hirschler LONDON, June 24 (Reuters) - AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive

LONDON BRIEFING: Broker Notes Move Shares As Market Awaits EU Summit